In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acuity Medical Inc.

Latest From Acuity Medical Inc.

WaveTec Prepares for a New Wave in Refractive Surgery

Refractive lens exchange is a mega opportunity in ophthalmology with the potential to serve the large patient populations with presbyopia and astigmatism. The category has been slow to take off, however, because current technology doesn't allow clinicians to meet, consistently and with confidence, the high expectations of new refractive surgery customers who are paying out of pocket for the benefit of great vision, at all distances. WaveTec has an enabling technology for a wide range of refractive surgeries to help clinicians and the many manufacturers of implantable intraocular lenses deliver on the promise of better vision.
Medical Device

Medtronic: Making Convergence Pay

Medtronic has been a pioneer in drug/device convergence: creating products whose therapeutic benefit stems equally from the features of their drug and device components. Convergence represents one of the medical device industry's most promising opportunities. But getting past the cultural differences between medical device and biotech companies can be huge.
BioPharmaceutical Medical Device

Start-Up Previews (11/05)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, The New Polymer Drugs, features profiles of Ilypsa, Midway Pharmaceuticals and PolyTherics. Plus these Start-Ups across Health Care: Acuity Medical, BeneChill, BrainCells, CellCentric and PolyMedix.

Acuity Medical Inc.

It's not known how age-related macular degeneration (AMD) converts from the dry, relatively benign form to the wet, sight-threatening form, or in which patients that progression is inevitable. It is known, however, that patients in the early stages face a 1.3 percent risk of developing wet AMD within five years, while people who have advanced to the intermediate stages of dry AMD face an 18% chance of progressing to the sight-threatening advanced dry or wet stages. For this latter group, Acuity Medical hopes to offer a safe, painless, non-invasive vision preserving device therapy for use in the physician's office and home care settings.
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Acuity Medical Inc.
  • Senior Management
  • Thomas A McColley, Pres.
  • Contact Info
  • Acuity Medical Inc.
    Phone: (810) 229-5828
    10524 Grand River
    Ste. 100
    Brighton, MI 48116-9559